Skip to main content
Caplight Logo









Neurolief

Neurolief

Private
NetanyaHealthcare & Life Scienceshttps://neurolief.com/

Last Round

Convertible Debt

Mar 26, 2026

Total Funding Raised

$22.05M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neurolief is a medical device company that develops non-invasive, wearable brain neuromodulation systems for the at-home treatment of neurological and neuropsychiatric disorders such as migraine and major depressive disorder.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Mental Health, Health IoT

Business Model

B2B2C

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

neuromodulationbrain stimulationat-home therapymajor depressive disorderMDDmigraine treatmentmedical deviceremote patient monitoringRPMdigital healthbioelectronic medicinetreatment-resistant depressionwearable medical devicetelehealthhealthcare analytics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurolief Comparables

Compare Neurolief with similar companies based on industry and business-model similarity.

Neurolief comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sooma
84%
Flow Neuroscience
83%
Theranica
82%

Neurolief Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMar 26, 2026
Convertible DebtAug 21, 2025
StrategicDec 28, 2023
Series AMay 9, 2018
Series AJun 1, 2017
Seed
Jan 1, 2015

Neurolief Investors

Notable investors and investment history

Neurolief investors
InvestorRounds
Champel CapitalSeries A
Terralab VenturesSeries A, Seed
KT SquaredSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 24, 80% of headcount.

  • Mar 26, 2026

    Raised $6M in early funding.

Recent news

Latest coverage and updates

  • signs_new_clientAug 11, 2026

    Neurolief signed new client Veterans Affairs on Aug 11th '26.

Neurolief Filings

Explore SEC and related filing metadata, where available.

Neurolief filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Neurolief's valuation, stock price, and market status.

Is Neurolief a public or private company?

Neurolief is a private company.

What is the current stock price of Neurolief?

Neurolief is a private company with no public stock price. No recent secondary market data is available.

How much is Neurolief worth (valuation)?

Valuation information for Neurolief is not publicly available.

Can I buy Neurolief stock?

Neurolief shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Neurolief's last funding round?

Neurolief's most recent funding round was Early Funding on March 26, 2026.

Who are the main investors in Neurolief?

Key investors in Neurolief include Terralab Ventures.

Will Neurolief IPO soon?

No public IPO plans have been announced for Neurolief.

How can I track Neurolief secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurolief's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNetanya
Employee Range24
Year Founded2013
Last FundingMar 26, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?